Soheil Sedaghat, Ommoleila Molavi, Akram Faridi, Ali Shayanfar and Mohammad Reza Rashidi Pages 1 - 5 ( 5 )
Background: Signal transducer and activator of transcription 3 (STAT3), an oncogenic protein found constitutively active in many types of human malignancies, is considered to be a promising target for cancer therapy. Objective: In this study for the first time, a simple and accurate method has been developed for the determination of a STAT3 dimerization inhibitor called stattic in aqueous and plasma samples. Method: A reverse-phase high-performance liquid chromatography (RP-HPLC) composed of C18 column as stationary phase, and the mixture of acetonitrile (60%) and water (40%) as mobile phase with a UV detection at 215 nm were applied for quantification of stattic. The developed method was validated by Food and Drug Administration (FDA) guideline. Results: The method provided a linear range between 1-40 and 2.5-40 μg mL-1 for aqueous and plasma samples, respectively, with a correlation coefficient of 0.999. The accuracy (as recovery) of the developed method was found to be between 95-105% for aqueous medium and 85-115% for plasma samples. The precision (as relative standard deviation) for aqueous and plasma samples was less than 6% and 15%, respectively. The sensitivity of the developed method based on FDA guideline was 1 μg mL-1 for aqueous and 2.5 μg mL-1 for plasma samples. Conclusion: These results show that the established method is a fast and accurate quantification for stattic in aqueous and plasma samples.
Analysis method, Cancer, HPLC-UV, Plasma, Stattic, Validation
abriz University of Medical Sciences, Medicinal Chemistry, Tabriz University of Medical Sciences Pharmacy, Tabriz University of Medical Sciences, Medicinal Chemistry, Tabriz University of Medical Sciences, Pharmacy, Tabriz University of Medical Sciences, Pharmacy